Francesco De Logu

This study shows that EP4 receptor internalization and compartmentalized signaling in DRG nociceptors mediate PGE2-induced pain, suggesting new strategies for inflammatory pain management.

The paper identifies a Schwann cell p75NTR-ROS-TRPA1 pathway that sustains persistent pain downstream of NGF, highlighting non-neuronal p75NTR signaling as a therapeutic target.

This study identifies synaptic vesicle endocytosis in nociceptors as a driver of chronic pain and shows that targeting it with CRISPR/dCas9-R via lipid nanoparticles provides long-lasting pain relief without affecting acute pain responses.

This paper introduces SynPARs, synthetic protease-activated receptors that enable cells to sense and respond to protease activity, demonstrating their use in counteracting hyperalgesia in mice.

This study identifies Schwann cell 5-HT1B/D signaling as a dual mediator of triptan efficacy and medication-overuse headache via TGF-β3-driven proalgesic pathways.

This study investigates the cell-specific roles of mutant TRPA1 in FEPS using mouse models, showing distinct contributions of neuronal and Schwann cell TRPA1 to pain mechanisms.

The paper identifies a druggable EP2 receptor in Schwann cells that encodes PG-mediated persistent inflammatory pain without affecting protective inflammation.

PoreMeth2 identifies differentially methylated regions using Nanopore sequencing, revealing epigenomic changes in cancer and glial cells.